PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients

Autor: Fotios Loupakis, Alfredo Falcone, Sergio Rizzo, Gaia Schiavon, Carla Rabitti, Pierfilippo Crucitti, Daniele Santini, Annamaria Ruzzo, Giuseppe Tonini, Giuseppe Perrone, Bruno Vincenzi, Anna Maria Frezza, Francesco Graziano, Antonio Russo, Andrea Onetti Muda, Alice Zoccoli, Sara Galluzzo
Přispěvatelé: Vincenzi B, Santini D, Perrone G, Graziano F, Loupakis, F, Schiavon, G, Frezza, AM, Ruzzo, AM, Rizzo, S, Crucitti, P, Galluzzo, S, Zoccoli, A, Rabitti, C, Muda, AO, Russo, A, Falcone, A, Tonini, G
Jazyk: angličtina
Rok vydání: 2012
Předmět:
Oncology
Male
Organoplatinum Compounds
Oxaloacetates
Physiology
Colorectal cancer
Settore MED/06 - Oncologia Medica
viruses
Clinical Biochemistry
Cell
Leucovorin
Promyelocytic Leukemia Protein
medicine.disease_cause
Deoxycytidine
Antineoplastic Combined Chemotherapy Protocols
biology
virus diseases
Nuclear Proteins
Middle Aged
Oxaliplatin
Survival Rate
medicine.anatomical_structure
Immunohistochemistry
oxaliplatin/fluoropyrimidine
Female
Fluorouracil
Colorectal Neoplasms
medicine.drug
Adult
medicine.medical_specialty
Antimetabolites
Antineoplastic
PML
colorectal cancer
Antineoplastic Agents
Promyelocytic leukemia protein
Predictive Value of Tests
Internal medicine
medicine
Humans
Capecitabine
Aged
Retrospective Studies
business.industry
Tumor Suppressor Proteins
Retrospective cohort study
Cell Biology
medicine.disease
Apoptosis
Drug Resistance
Neoplasm
biology.protein
Carcinogenesis
business
Transcription Factors
Popis: PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy. Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry. PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients with PML down-regulation than in patients with preserved PML expression (60%) (P = 0.006). Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P
Databáze: OpenAIRE
Externí odkaz: